Person
David Graham
FDA drug-safety scientist who testified to the Senate Finance Committee on Vioxx in November 2004.
Connections 3
worked at
- U.S. Food and Drug Administration Associate Director for Science and Medicine, Office of Drug Safety Primary record 1
involved in
- Senate Finance Committee hearing on Vioxx (2004) testified Primary record 1
authored
- Testimony of David J. Graham, November 18, 2004 18 Nov 2004 Primary record 1
Timeline 1 date
- 18 Nov 2004 David Graham authored Testimony of David J. Graham, November 18, 2004
Proof 1 source
-
Testimony of David J. Graham, MD, MPH, November 18, 2004, U.S. Senate Committee on Finance, 18 Nov 2004.
Primary record
Archived copy
I am currently the Associate Director for Science and Medicine in FDA’s Office of Drug Safety.
Mr. Chairman and members of the Committee,
Testimony of David J. Graham, MD, MPH, November 18, 2004
Among many things, this report estimated that nearly 28,000 excess cases of heart attack or sudden cardiac death were caused by Vioxx.
This estimate ranges from 88,000 to 139,000 Americans.
I was pressured to change my conclusions and recommendations
regulate as its client, over-values the benefits of the drugs it approves and seriously under-values,
Page history 1 change
- Add 55 stories, each checked against its sources96e92fe6
Something wrong or missing? Tell us, with a source, or edit this page.